

# Change in *Salmonella* Typhi incidence and antimicrobial resistance patterns following mass vaccination with the new typhoid conjugate vaccine

#### Ioana D Olaru

N. Feasey, R. Ferrand, J. Martin, D. Mabey, H. Hopkins, S. Zinyowera, P. Chonzi, K. Kranzer










### **Typhoid fever in Harare**



- Typhoid fever outbreak in Harare since 2016
- Usually seasonal with more cases in the rainy season
- Main causes:
  - inappropriate disposal of sewage
  - contaminated communal boreholes
  - water shortages





### FIEBRE Study





Recruiting adults and children ≥2 months presenting with fever at primary care clinics and hospitals in Harare

### FIEBRE Study



#### **AIMS**

To identify the causes of fever, and the antimicrobial susceptibility of bacterial pathogens causing fever, in low- and middle-income countries from where few data are available.


**4 countries:** Lao PDR, Malawi, Mozambique and Zimbabwe Patient recruitment started in June 2018 in Zimbabwe

Broad range of diagnostic tests for bacteria, viruses, fungi and parasites

1 aerobic blood culture is collected for all study participants

## FIEBRE study clinics





#### **Methods**



- AIM: describe the impact of typhoid conjugate vaccine (TCV)
  mass vaccination on S. Typhi cases and antimicrobial resistance
  (AMR) in Harare
- Automated blood culture system (BacT/ALERT, Biomerieux)
- Identification of isolates using biochemical tests (API 20E, Biomerieux)
- Suspected S. Typhi isolates confirmed by serotyping at the National Microbiology Reference Laboratory
- Drug susceptibility testing: EUCAST standards
  - Disc-diffusion for ampicillin, chloramphenicol, co-trimoxazole, ceftriaxone
  - Pefloxacin discs were used to screen for fluoroquinolone resistance.
  - E-Tests were used for azithromycin and ciprofloxacin.

### Results




| OUTPATIENTS            | Children<br>(<15 years)<br>N=525 | Adults<br>(≥15 years)<br>N=605 | Total<br>N=1130 |
|------------------------|----------------------------------|--------------------------------|-----------------|
| Confirmed              | 50 (9.5%)                        | 147 (24.3%)                    | 197 (17.4%)     |
| Suspected or confirmed | 183 (34.9%)                      | 291 (48.1%)                    | 474 (41.9%)     |

Confirmed typhoid fever case – positive blood culture with S. Typhi Suspected typhoid fever case – according to the diagnosis made at the clinic

## Participant characteristics





|              | Typhoid | Blood culture<br>negative |
|--------------|---------|---------------------------|
| Male         | 47%     | 47%                       |
| Age (median) | 21      | 18                        |
| HIV+         | 3%      | 6%                        |

#### **Symptoms**

Headache 94% Abdominal pain 73% Vomiting 13%


# Typhoid fever cases according to age



Mass vaccination campaign of children <15 years with the typhoid conjugate vaccine (TCV) in March 2019


#### **Vaccination coverage:**

- 72% in pre-school children
- 97% in school going children




# Impact of vaccination with typhoid conjugate vaccine






# Drug susceptibility testing





**No S. Typhi isolates were resistant to ceftriaxone or azithromycin**  $MDR = resistance \ to \ amoxicillin + chloramphenicol + co-trimoxazole$ 

# Decreased ciprofloxacin susceptibility according to age STROPICAL MEDICINE




DCS: decreased ciprofloxacin susceptibility

# MIC distribution for ciprofloxacin




Decreased susceptibility to ciprofloxacin (DCS) if MIC >0.06 (poor treatment response)



All isolates with pefloxacin resistance by disc diffusion had ciprofloxacin MICs >0.06

# MIC distribution for azithromycin





#### Conclusion



- Decrease in the prevalence of DCS following the TCV mass vaccination campaign.
  - ? localized point-source outbreak ended by vaccination
- Vaccination led to a reduction of typhoid fever cases among children presenting to primary healthcare
- High number of cases identified post-vaccination campaign (mostly adults)
  - need for further control measures to control the outbreak

### Acknowledgements



# BRTI laboratory Janice Martin Forget Makoga

**Beauty Makamure** 





LSHTM
David Mabey
Heidi Hopkins
Katharina Kranzer
Rashida Ferrand



**Harare City Health** 

Prosper Chonzi

The doctors and nurses from the clinics

**National Microbiology Reference Laboratory** 





FIEBRE Field team
The study participants







# Thank you!



